FAKTOR-ZERTIFIKAT - VERTEX PHARMACEUTICALS | Market Closed - Börse Stuttgart 20:49:59 07/06/2024 BST | ||
| 0.66 EUR | +1.54% |
|
| Current month | -40.91% | ||
| 1 month | -77.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 0.66 | +1.54% |
| 06/06/24 | 0.65 | -4.41% |
| 05/06/24 | 0.68 | -11.69% |
| 04/06/24 | 0.77 | -13.48% |
| 03/06/24 | 0.89 | -19.09% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 08:49 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JK2LTP |
| ISIN | DE000JK2LTP7 |
| Date issued | 23/02/2024 |
| Strike | 554.9 $ |
| Maturity | Unlimited |
| Parity | 103.36 : 1 |
| Emission price | 2.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.91 € |
|---|---|
| Lowest since issue | 0.65 € |
| Spread | 0.04 € |
| Spread % | 5.63% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
485.5
USD
Average target price
463.5
USD
Spread / Average Target
-4.53%
- Stock Market
- Certificates
- Certificat